Plus Therapeutics and SpectronRx Form Radiotherapeutic Manufacturing Partnership

Plus Therapeutics, Inc., a pharmaceutical company in the clinical stage known for its development of targeted radiotherapeutics, has entered into a significant Manufacturing Services Agreement (MSA) with SpectronRx. This collaboration focuses on producing Rhenium (186Re) Obisbemeda, a cutting-edge radiotherapy aimed at treating central nervous system (CNS) cancers, including leptomeningeal metastases and recurrent glioblastoma.

Dr. Marc H. Hedrick, the President and CEO of Plus Therapeutics, expressed the company's intentions to commence late-stage clinical trials in 2025. To prepare for the anticipated demand at the commercial level, expanding the supply chain has become crucial. Partnering with SpectronRx, a leader in radiopharmaceutical manufacturing, is seen as a strategic move to meet these future demands effectively.

SpectronRx will leverage its advanced facilities and expertise to produce both late-stage clinical and commercial quantities of Rhenium (186Re) Obisbemeda. With over 170,000 square feet dedicated to radiopharmaceutical contract development and manufacturing, the company operates across five locations with a workforce of 150 employees. Currently serving 29 countries and collaborating with more than 31 pharmaceutical companies, SpectronRx is well-positioned to advance nuclear medicine.

Anwer Rizvi, President of SpectronRx, highlighted the company's pride in partnering with Plus Therapeutics. He emphasized their commitment to the advancement of nuclear medicine and the provision of high-quality radiotherapies. This partnership is expected to bolster SpectronRx’s mission and enhance patient access to innovative treatments like Rhenium (186Re) Obisbemeda.

The strategic alliance between Plus Therapeutics and SpectronRx is geared towards ensuring robust supply chain redundancy and meeting the demands of impending late-stage clinical trials and eventual commercial needs. This agreement represents a pivotal step in broadening the availability and impact of Rhenium (186Re) Obisbemeda.

Rhenium (186Re) Obisbemeda is an injectable radiotherapy designed to deliver high-dose radiation directly to CNS tumors. This targeted approach aims to optimize patient outcomes by reducing off-target risks and improving the efficacy of CNS cancer treatments compared to existing therapies. The radioisotope Rhenium-186 is particularly suitable for CNS applications due to its favorable properties, including a short half-life and beta energy for tumor destruction coupled with gamma energy for real-time imaging.

Currently, Rhenium (186Re) Obisbemeda is undergoing evaluation in clinical trials for recurrent glioblastoma and leptomeningeal metastases, specifically in the ReSPECT-GBM and ReSPECT-LM trials. Notably, the ReSPECT-GBM trial is supported by the National Cancer Institute (NCI) under the U.S. National Institutes of Health (NIH), while ReSPECT-LM is funded by a substantial grant from the Cancer Prevention & Research Institute of Texas (CPRIT).

Plus Therapeutics focuses on developing targeted radiotherapeutics for challenging CNS cancers, aiming to improve clinical outcomes through image-guided local beta radiation and targeted drug delivery. The company’s product pipeline predominantly targets recurrent glioblastoma and leptomeningeal metastases. With operations based in key cancer research hubs in Austin and San Antonio, Texas, Plus Therapeutics has established a strategic network of partnerships to support the development, manufacturing, and potential commercialization of its products.

SpectronRx specializes in developing and manufacturing diagnostic and therapeutic radiopharmaceuticals. Their expertise spans radiopharmaceutical contract development, manufacturing, and isotope production. The company’s extensive facilities and experienced personnel enable it to expedite the development and market introduction of new medicines, thus enhancing patient care and generating profitability for their clients. With a global reach, SpectronRx supplies radiopharmaceuticals to numerous countries and has received inspections from both the EMA and FDA.

In summary, the cooperation between Plus Therapeutics and SpectronRx aims to advance the production and development of Rhenium (186Re) Obisbemeda, thereby providing improved treatment options for CNS cancer patients.